Department of Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia.
School of Medicine, University of Zagreb, Zagreb, Croatia.
Expert Opin Biol Ther. 2024 Oct;24(10):1017-1024. doi: 10.1080/14712598.2024.2405562. Epub 2024 Sep 19.
In the era of immunotherapy, bevacizumab seems to be losing its place in NSCLC treatment algorithms. The aim of this work is to try to define the advantages and disadvantages of NSCLC treatment with bevacizumab in combination regimens.
We conducted a literature search in PubMed and Google Scholar to review the most important topics regarding bevacizumab treatment in NSCLC, with or without driver mutations, including trials with checkpoint inhibitors. Special emphasis was placed on the analysis of data on the treatment of patients with CNS metastases.
Bevacizumab is an antiangiogenic compound whose addition to chemotherapy made the first major breakthrough in the treatment of NSCLC. However, for the last 10 years or so, the use of combination immunotherapy regimens has suppressed the use and acquisition of new knowledge about bevacizumab. Newer data are primarily related to the treatment of EGFR-positive NSCLC patients with bevacizumab, with only a few larger studies investigating the use of a combination of bevacizumab and checkpoint inhibitors. The basic task remains to define the place of bevacizumab in treatment algorithms.
在免疫治疗时代，贝伐珠单抗似乎正在失去其在 NSCLC 治疗方案中的地位。本研究旨在尝试确定贝伐珠单抗联合治疗方案治疗 NSCLC 的优缺点。
我们在 PubMed 和 Google Scholar 上进行了文献检索，以综述 NSCLC 治疗中（有无驱动基因突变）贝伐珠单抗治疗的最重要课题，包括与检查点抑制剂的临床试验。特别强调对 CNS 转移患者治疗数据的分析。
贝伐珠单抗是一种抗血管生成化合物，其与化疗联合使用是 NSCLC 治疗的首次重大突破。然而，在过去 10 年左右的时间里，免疫联合治疗方案的应用抑制了对贝伐珠单抗的使用和新知识的获取。新数据主要与贝伐珠单抗治疗 EGFR 阳性 NSCLC 患者有关，只有少数较大的研究调查了贝伐珠单抗与检查点抑制剂联合应用。基本任务仍然是确定贝伐珠单抗在治疗方案中的地位。
